Caligan Partners LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 13, 2024), Caligan Partners LP reported 12 stock positions worth $378.3 million. Its top holding was Liquidia (LQDA) at 40.4% of the portfolio, followed by Alimera Sciences (ALIM, 17.4%) and Anika Therapeutics (ANIK, 9.6%). Compared with Q4 2023, it opened 4 new positions, sold out of 3, added to 5 and reduced 1. The biggest buy was Verona Pharma (VRNA, shares +608%) and the biggest sale an exit from Standard Biotools (LAB).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001727492
- Portfolio Value
- $378.3M (Q1 2024)
- SEC Filing
- 0001727492-24-000006 ↗ filed May 13, 2024
Holdings Value
Holdings 12 stocks · $378.3M
| LQDA Liquidia Corp. | 40.40% | 10,360,945 | $152.8M | No change |
| ALIM Alimera Sciences Inc. | 17.36% | 16,835,154 | $65.7M | No change |
| ANIK Anika Therapeutics Inc. | 9.64% | 1,435,993 | $36.5M | Add +32.8% |
| EOLS Evolus Inc. | 6.99% | 1,888,881 | $26.4M | Add +43.3% |
| EXEL Exelixis Inc. | 6.90% | 1,100,730 | $26.1M | Add +20.9% |
| VRNA Verona Pharma Ltd. | 5.51% | 1,296,447 | $20.9M | Add +608.2% |
| ENTA Enanta Pharmaceuticals Inc. | 3.96% | 858,070 | $15.0M | New |
| AGIO Agios Pharmaceuticals Inc. | 3.75% | 484,711 | $14.2M | Add +9.7% |
| YMAB Y-Mabs Therapeutics Inc. | 2.52% | 587,276 | $9.5M | Reduce -44.0% |
| OTLK Outlook Therapeutics Inc. | 1.58% | 500,000 | $6.0M | New |
| BCRX Biocryst Pharmaceuticals Inc. | 1.02% | 758,502 | $3.9M | New |
| NBP Novabridge Biosciences filed as I MAB | 0.37% | 756,538 | $1.4M | New |
Portfolio Sells Q4 2023 → Q1 2024
Portfolio Buys Q4 2023 → Q1 2024
| VRNA Verona Pharma Ltd. | Add +608.2% | 5.51% | +4.29 |
| ENTA Enanta Pharmaceuticals Inc. | New | 3.96% | +3.96 |
| EOLS Evolus Inc. | Add +43.3% | 6.99% | +2.31 |
| OTLK Outlook Therapeutics Inc. | New | 1.58% | +1.58 |
| ANIK Anika Therapeutics Inc. | Add +32.8% | 9.64% | +1.38 |
| BCRX Biocryst Pharmaceuticals Inc. | New | 1.02% | +1.02 |
| AGIO Agios Pharmaceuticals Inc. | Add +9.7% | 3.75% | +0.43 |
| NBP Novabridge Biosciences | New | 0.37% | +0.37 |
| EXEL Exelixis Inc. | Add +20.9% | 6.90% | −0.46 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $2.1B | LQDA, RVMD, ABVX, PCVX, EXEL |
| Q1 2026 | 24 | $1.4B | LQDA, ABVX, RVMD, PCVX, XENE |
| Q4 2025 | 20 | $1.1B | LQDA, ABVX, RVMD, MLYS, PCVX |
| Q3 2025 | 16 | $720.7M | LQDA, ABVX, MLYS, EXEL, RVMD |
| Q2 2025 | 16 | $515.1M | VRNA, LQDA, EXEL, AGIO, MRUS |
| Q1 2025 | 16 | $479.2M | LQDA, VRNA, EXEL, MLYS, EOLS |
| Q4 2024 | 14 | $394.9M | LQDA, VRNA, EXEL, EOLS, ANIK |
| Q3 2024 | 12 | $315.5M | LQDA, VRNA, EXEL, EOLS, ANIK |
| Q2 2024 | 13 | $428.0M | LQDA, ALIM, ANIK, EXEL, BCRX |
| Q1 2024 | 12 | $378.3M | LQDA, ALIM, ANIK, EOLS, EXEL |